ATHE - ALTERITY THERAPEUTICS LTD
Previous close
3.07
-0.200 -6.515%
Share volume: 725
Last Updated: Fri 27 Dec 2024 07:53:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$3.27
-0.20
-6.12%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
31.21%
1 Month
188.90%
3 Months
137.66%
6 Months
76.91%
1 Year
22.53%
2 Year
2.27%
Key data
Stock price
$3.07
DAY RANGE
$2.96 - $3.28
52 WEEK RANGE
$1.09 - $3.19
52 WEEK CHANGE
$26.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: David A. Stamler
Region: US
Website: alteritytherapeutics.com
Employees: 10
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alteritytherapeutics.com
Employees: 10
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's Disease.
Recent news